SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-001110
Filing Date
2023-05-12
Accepted
2023-05-12 17:15:48
Documents
57
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q scps-20230331x10q.htm   iXBRL 10-Q 832595
2 EX-31.1 scps-20230331xex31d1.htm EX-31.1 12759
3 EX-31.2 scps-20230331xex31d2.htm EX-31.2 12788
4 EX-32.1 scps-20230331xex32d1.htm EX-32.1 6108
5 EX-32.2 scps-20230331xex32d2.htm EX-32.2 6132
  Complete submission text file 0001410578-23-001110.txt   3919908

Data Files

Seq Description Document Type Size
6 EX-101.SCH scps-20230331.xsd EX-101.SCH 45333
7 EX-101.CAL scps-20230331_cal.xml EX-101.CAL 24884
8 EX-101.DEF scps-20230331_def.xml EX-101.DEF 139669
9 EX-101.LAB scps-20230331_lab.xml EX-101.LAB 343092
10 EX-101.PRE scps-20230331_pre.xml EX-101.PRE 254815
51 EXTRACTED XBRL INSTANCE DOCUMENT scps-20230331x10q_htm.xml XML 431062
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39788 | Film No.: 23917017
SIC: 2834 Pharmaceutical Preparations